Uno studio che valuta l'efficacia e la sicurezza di Mitapivat nei partecipanti con alfa- o beta-talassemia dipendente dalla trasfusione (α- o β-TDT) (ENERGIZE-T)
Uno studio di fase 3, in doppio cieco, randomizzato, controllato con placebo, multicentrico che valuta l'efficacia e la sicurezza di mitapivat in soggetti con alfa- o beta-talassemia dipendente dalle trasfusioni (ENERGIZE-T)
The primary objective of this study was to compare the effect of mitapivat versus placebo on transfusion burden in participants with α- or β-transfusion-dependent thalassemia.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
The mitapivat group included 171 participants. The placebo group included 87 participants.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Riyadh, Arabia Saudita, 14611
- King Abdullah International Medical Research Center
-
Riyadh, Arabia Saudita, 90210
- King Khalid University Hospital
-
-
-
-
-
Ribeirão Preto, Brasile, 14051-260
- Hospital Das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP
-
São Paulo, Brasile, 04006-002
- GSH Banco de Sangue de São Paulo
-
-
-
-
-
Kyustendil, Bulgaria, 2500
- MHAT "Dr. Nikola Vasiliev" AD
-
Pleven, Bulgaria, 5800
- UMHAT "Dr. Georgi Stranski" Pleven
-
Plovdiv, Bulgaria, 4002
- UMHAT "Sveti Georgi" EAD
-
Sofia, Bulgaria, 1756
- SHATHD Sofia
-
Stara Zagora, Bulgaria, 6000
- UMHAT "Prof. Dr. Stoyan Kirkovich"
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 2T9
- Foothills Medical Centre
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- Toronto General Hospital, University Health Network
-
-
-
-
-
Hovedstaden, Danimarca, 2100
- Rigshospitalet
-
-
-
-
-
Abu Dhabi, Emirati Arabi Uniti
- Burjeel Medical City
-
-
-
-
-
Créteil, Francia, 94010
- CHU Hôpital Henri Mondor
-
Lyon, Francia, 69003
- Hôpital Edouard Herriot, CHU de Lyon
-
Marseille, Francia, 13385
- CHU Hôpital de la Timone
-
Paris, Francia, 75015
- Hôpital Necker Enfants Malades
-
-
-
-
-
Berlin, Germania, 13353
- Charité - UB - CVK - Medizinische Klinik
-
Essen, Germania, 45122
- Universitätsklinikum Essen
-
Leipzig, Germania, 04103
- Universitätsklinikum Leipzig
-
-
-
-
-
Achaia, Grecia, 26504
- University General Hospital of Patras
-
Athens, Grecia, 11527
- Children's Hospital Agia Sophia, National and Kapodistrian University of Athens Medical School
-
Athens, Grecia, 115 26
- Laiko General Hospital
-
Ioannina, Grecia, 455 00
- University Hospital of Ioannina
-
Thessaloniki, Grecia, 546 42
- Ippokrateio General Hospital
-
-
-
-
-
Brindisi, Italia, 72100
- Ospedale "A. Perrino" - Brindisi
-
Cagliari, Italia, 09121
- Ospedale Pediatrico Microcitemico
-
Ferrara, Italia, 44124
- Ospedale Sant'Anna
-
Genova, Italia, 16128
- Ente Ospedaliero Ospedali Galliera
-
Milan, Italia, 20122
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
Modena, Italia, 41124
- A.O.U Di Modena
-
Naples, Italia, 80138
- AOU L. Vanvitelli Universita degli Studi della Campania Luigi Vanvitelli
-
Orbassano, Italia, 10043
- A.O.U. San Luigi Gonzaga
-
-
-
-
-
Beirut, Libano, 9999
- Chronic Care Center
-
-
-
-
-
Alor Star, Malaysia, 05460
- Hospital Sultanah Bahiyah
-
Johor Bahru, Malaysia, 80100
- Hospital Sultanah Aminah Johor Bahru
-
Kota Kinabalu, Malaysia, 88586
- Hospital Queen Elizabeth, Kota Kinabalu
-
Kuala Lumpur, Malaysia, 50300
- Hospital Tunku Azizah
-
Kuantan, Malaysia, 25100
- Hospital Tengku Ampuan Afzan
-
Kuching, Malaysia, 93586
- Hospital Umum Sarawak
-
Pandan Indah, Malaysia, 68000
- Hospital Ampang
-
Pulau Pinang, Malaysia, 10990
- Hospital Pulau Pinang
-
-
-
-
-
Amsterdam, Olanda, 1105 AZ
- Amsterdam Universitair Medisch Centrum, Locatie AMC
-
Utrecht, Olanda, 3584 CX
- Universitair Medisch Centrum Utrecht
-
Westzeedijk 353, Olanda, 3015 AA
- Erasmus MC
-
-
-
-
-
London, Regno Unito, WC1E 6BT
- University College London
-
London, Regno Unito, W12 0HS
- Imperial College Healthcare NHS Trust - Hammersmith Hospital
-
-
-
-
-
Barcelona, Spagna, 08035
- Hospital Universitario Vall d'Hebron
-
Madrid, Spagna, 28046
- Hospital Universitario La Paz
-
Murcia, Spagna, 30120
- Hospital Universitario Virgen Arrixaca
-
Seville, Spagna, 41013
- Hospital Universitario Virgen del Rocío
-
-
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85016-7710
- Phoenix Children's Hospital
-
-
California
-
La Jolla, California, Stati Uniti, 92093
- San Diego Hospital, UC San Diego Health
-
Oakland, California, Stati Uniti, 94609-1809
- Children's Hospital Oakland
-
Palo Alto, California, Stati Uniti, 94304-1601
- Stanford Medicine
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02115
- Boston Children's Hospital
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48201-2196
- Children's Hospital of Michigan
-
-
New York
-
New York, New York, Stati Uniti, 10065-4870
- Weill Cornell Medical Center
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27710-3038
- Duke University Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Penn Medicine - University of Pennsylvania Health System
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98101
- Seattle Cancer Care Alliance, University of Washington
-
-
-
-
-
Bangkok, Tailandia, 10400
- Phramongkutklao Hospital
-
Bangkok, Tailandia, 10400
- Ramathibodi Hospital
-
Bangkok, Tailandia, 10700
- Faculty of Medicine Siriraj Hospital
-
Chiang Mai, Tailandia, 50200
- Maharaj Nakorn Chiang Mai Hospital
-
Khon Kaen, Tailandia, 40000
- Srinagarind Hospital, Khon Kaen University
-
Mueang Phitsanulok, Tailandia, 65000
- Naresuan University Hospital
-
Pathum Wan, Tailandia
- King Chulalongkorn Memorial Hospital
-
-
-
-
-
Taipei, Taiwan, 100
- National Taiwan University Hospital
-
-
-
-
-
Adana, Turchia (Türkiye), 1130
- Acibadem Adana Hospital
-
Antalya, Turchia (Türkiye), 07059
- Akdeniz University Faculty of Medicine
-
Balcalı, Turchia (Türkiye), 01330
- Çukurova University
-
Bornova, Turchia (Türkiye), 35040
- Ege University Faculty of Medicine
-
Fatih, Turchia (Türkiye), 34093
- Istanbul University Faculty of Medicine
-
Mersin, Turchia (Türkiye)
- Hacettepe University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Greater than or equal to (≥)18 years of age at the time of providing informed consent;
- Documented diagnosis of thalassemia (β-thalassemia with or without α-globin gene mutations, hemoglobin E (HbE)/β-thalassemia, or α-thalassemia/hemoglobin H (HbH) disease) based on deoxyribonucleic acid (DNA) analysis;
- Considered transfusion-dependent, defined as 6 to 20 red blood cells (RBC) units transfused and ≤6-week transfusion-free period during the 24-week period before randomization;
- If taking hydroxyurea, the hydroxyurea dose must be stable for ≥16 weeks before randomization;
- Women of childbearing potential (WOCBP) must be abstinent of sexual activities that may induce pregnancy as part of their usual lifestyle or agree to use two forms of contraception, one of which must be considered highly effective, from the time of providing informed consent, throughout the study, and for 28 days after the last dose of study drug. The second form of contraception can be an acceptable barrier method;
- Written informed consent before any study-related procedures are conducted and willing to comply with all study procedures for the duration of the study.
Exclusion Criteria:
-
Pregnant, breastfeeding, or parturient;
-
Documented history of homozygous or heterozygous sickle hemoglobin (Hb S) or hemoglobin C (Hb C);
-
Prior exposure to gene therapy or prior bone marrow or stem cell transplantation;
-
Currently receiving treatment with luspatercept; the last dose must have been administered ≥36 weeks before randomization;
-
Currently receiving treatment with hematopoietic stimulating agents; the last dose must have been administered ≥36 weeks before randomization;
-
History of malignancy (active or treated) ≤5 years before providing informed consent, except for nonmelanomatous skin cancer in situ, cervical carcinoma in situ, or breast carcinoma in situ;
-
History of active and/or uncontrolled cardiac or pulmonary disease ≤6 months before providing informed consent;
-
Hepatobiliary disorders;
-
Estimated glomerular filtration rate <45 milliliters per minute (mL/min)/1.73 meter (m)^2 by Chronic Kidney Disease Epidemiology Collaboration creatinine equation;
-
Nonfasting triglycerides >440 milligrams per deciliter (mg/dL) (5 millimoles per liter [mmol/L]);
-
Active infection requiring systemic antimicrobial therapy at the time of providing informed consent;
-
Positive test for hepatitis C virus antibody (HCVAb) with evidence of active HCV infection, or positive test for hepatitis B surface antigen (HBsAg);
-
Positive test for human immunodeficiency virus (HIV)-1 antibody (Ab) or HIV-2 Ab;
-
History of major surgery (including splenectomy) ≤6 months before providing informed consent and/or a major surgical procedure planned during the study;
-
Current enrollment or past participation (≤12 weeks before administration of the first dose of study drug or a timeframe equivalent to 5 half-lives of the investigational study drug, whichever is longer) in any other clinical study involving an investigational treatment or device;
-
Receiving strong CYP3A4/5 inhibitors that have not been stopped for ≥5 days or a timeframe equivalent to 5 half-lives (whichever is longer); or strong CYP3A4 inducers that have not been stopped for ≥4 weeks or a timeframe equivalent to 5 half-lives (whichever is longer), before randomization;
-
Receiving anabolic steroids that have not been stopped for at least 4 weeks before randomization. Testosterone replacement therapy to treat hypogonadism is allowed. The testosterone dose and preparation must be stable for ≥12 weeks before randomization;
-
Known allergy, or other contraindication, to mitapivat or its excipients (microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, mannitol, and magnesium stearate, Opadry® II Blue [hypromellose, titanium dioxide, lactose monohydrate, triacetin, and Federal Food, Drug, and Cosmetic (FD&C) Blue #2]);
-
Any medical, hematological, psychological, or behavioral condition(s) or prior or current therapy that, in the opinion of the Investigator, may confer an unacceptable risk to participating in the study and/or could confound the interpretation of the study data. Also excluded are:
- Participants who are institutionalized by regulatory or court order
- Participants with any condition(s) that could create undue influence (including but not limited to incarceration, involuntary psychiatric confinement, and financial or familial affiliation with the Investigator or Sponsor).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Mitapivat
Participants randomized to receive mitapivat 100 milligrams (mg), orally, twice daily (BID) for 48 weeks in the double-blind (DB) period and for up to 5 years in the open label extension (OLE) period. |
Tablets
Altri nomi:
|
|
Comparatore placebo: Placebo
Participants randomized to receive placebo matching mitapivat, orally, BID for 48 weeks in the DB period followed by mitapivat 100 mg, orally, BID for up to 5 years in the OLE period. |
Tablets
Altri nomi:
Tablets |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Double-blind Period: Percentage of Participants Who Achieved Transfusion Reduction Response (TRR)
Lasso di tempo: Double-blind Period: Baseline through Week 48
|
TRR is defined as ≥50% reduction in transfused red blood cells (RBC) units with a reduction of ≥2 units of transfused RBCs in any consecutive 12-week period through Week 48 compared with baseline transfusion burden standardized to 12 weeks. Baseline transfusion burden standardized to 12 weeks= (12/24) × total number of RBC units transfused during 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 12 (Day 85) were considered nonresponders. |
Double-blind Period: Baseline through Week 48
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Periodo in doppio cieco: concentrazioni plasmatiche di mitapivat
Lasso di tempo: Periodo in doppio cieco: pre-dose alla settimana 12; Pre-dose alla settimana 24; Pre-dose, 0,5, 1, 3, 5, 7 ore dopo la dose alla settimana 36
|
Periodo in doppio cieco: pre-dose alla settimana 12; Pre-dose alla settimana 24; Pre-dose, 0,5, 1, 3, 5, 7 ore dopo la dose alla settimana 36
|
|
|
Periodo in doppio cieco: concentrazione plasmatica massima osservata (CMAX) di Mitapivat
Lasso di tempo: Periodo in doppio cieco: pre-dose, 0,5, 1, 3, 5, 7 ore post-dose settimana 36
|
Periodo in doppio cieco: pre-dose, 0,5, 1, 3, 5, 7 ore post-dose settimana 36
|
|
|
Periodo in doppio cieco: tempo a raggiungere la massima concentrazione plasmatica osservata (Tmax) di Mitapivat
Lasso di tempo: Periodo in doppio cieco: pre-dose, 0,5, 1, 3, 5, 7 ore post-dose settimana 36
|
Periodo in doppio cieco: pre-dose, 0,5, 1, 3, 5, 7 ore post-dose settimana 36
|
|
|
Periodo in doppio cieco: tempo dell'ultima concentrazione quantificabile (TLAST) di Mitapivat
Lasso di tempo: Periodo in doppio cieco: pre-dose, 0,5, 1, 3, 5, 7 ore post-dose settimana 36
|
Periodo in doppio cieco: pre-dose, 0,5, 1, 3, 5, 7 ore post-dose settimana 36
|
|
|
Periodo in doppio cieco: concentrazione ematica di adenosina trifosfato (ATP)
Lasso di tempo: Periodo in doppio cieco: pre-dose al giorno 1; Pre-dose alla settimana 12; Pre-dose alla settimana 24; Pre-dose, 0,5, 1, 3, 5, 7 ore dopo la dose alla settimana 36
|
Periodo in doppio cieco: pre-dose al giorno 1; Pre-dose alla settimana 12; Pre-dose alla settimana 24; Pre-dose, 0,5, 1, 3, 5, 7 ore dopo la dose alla settimana 36
|
|
|
Periodo in doppio cieco: concentrazione ematica di 2,3-difosfoglicerato (2,3-dpg)
Lasso di tempo: Periodo in doppio cieco: pre-dose al giorno 1; Pre-dose alla settimana 12; Pre-dose alla settimana 24; Pre-dose, 0,5, 1, 3, 5, 7 ore dopo la dose alla settimana 36
|
Periodo in doppio cieco: pre-dose al giorno 1; Pre-dose alla settimana 12; Pre-dose alla settimana 24; Pre-dose, 0,5, 1, 3, 5, 7 ore dopo la dose alla settimana 36
|
|
|
Double-blind Period: Percentage of Participants Who Achieved TRR2
Lasso di tempo: Double-blind period: Baseline through Week 48
|
TRR2, defined as a ≥50% reduction in transfused RBC units in any consecutive 24-week period through Week 48 compared with the 24-week baseline transfusion burden, is reported. Baseline transfusion burden standardized to 24 weeks is the total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 24 (Day 169) were considered nonresponders. |
Double-blind period: Baseline through Week 48
|
|
Double-blind Period: Percentage of Participants Who Achieved TRR3
Lasso di tempo: Double-blind period: Baseline up to Week 13 through Week 48
|
TRR3, defined as a ≥33% reduction in transfused RBC units from Week 13 through Week 48 compared with the baseline transfusion burden standardized to 36 weeks, is reported. Baseline transfusion burden standardized to 36 weeks= (36/24) × total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 48 were considered nonresponders. |
Double-blind period: Baseline up to Week 13 through Week 48
|
|
Double-blind Period: Percentage of Participants Who Achieved TRR4
Lasso di tempo: Double-blind period: Baseline up to Week 13 through Week 48
|
TRR4, defined as a ≥50% reduction in transfused RBC units from Week 13 through Week 48 compared with the baseline transfusion burden standardized to 36 weeks, is reported. Baseline transfusion burden standardized to 36 weeks = (36/24) × total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 48 were considered nonresponders. |
Double-blind period: Baseline up to Week 13 through Week 48
|
|
Double-blind Period: Percent Change From Baseline in Transfused RBC Units
Lasso di tempo: Double-blind Period: Baseline, Week 13 through Week 48
|
Transfusion burden from Week 13 through Week 48 standardized to 36 weeks is defined as number of transfused RBC units from Day 85 through Week 48 in the Double-blind Period ×36/(Number of days from Day 85 through Week 48 in the Double-blind Period/7). Baseline transfusion burden standardized to 36 weeks= (36/24)× is the total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or within 168 days before the start of study treatment for participants randomized and dosed. |
Double-blind Period: Baseline, Week 13 through Week 48
|
|
Double-blind Period: Percentage of Participants Who Achieved Transfusion-Independence
Lasso di tempo: Double-blind Period: Baseline through Week 48
|
Transfusion-independence is defined as transfusion-free for ≥8 consecutive weeks through Week 48 in the double-blind period. |
Double-blind Period: Baseline through Week 48
|
|
Double-blind Period: Change From Baseline in Iron Levels
Lasso di tempo: Double-blind Period: Baseline through Week 48
|
Iron metabolism was assessed based on Iron levels. |
Double-blind Period: Baseline through Week 48
|
|
Double-blind Period: Change From Baseline in Serum Ferritin Levels
Lasso di tempo: Double-blind Period: Baseline through Week 48
|
Iron metabolism was assessed based on serum ferritin levels. |
Double-blind Period: Baseline through Week 48
|
|
Double-blind Period: Change From Baseline in Total Iron Binding Capacity
Lasso di tempo: Double-blind Period: Baseline through Week 48
|
Iron metabolism was assessed based on total iron binding capacity. |
Double-blind Period: Baseline through Week 48
|
|
Double-blind Period: Change From Baseline in Transferrin Saturation (TSAT) Levels
Lasso di tempo: Double-blind Period: Baseline through Week 48
|
Iron metabolism was assessed based on TSAT levels. Transferrin saturation is reported by dividing value of serum iron by total iron binding capacity. |
Double-blind Period: Baseline through Week 48
|
|
Double-blind Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs With Severity Greater Than or Equal to Grade 3
Lasso di tempo: Double-blind Period: From first dose of study drug up to week 48
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious & non-serious TEAEs. Severity of AEs was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE. |
Double-blind Period: From first dose of study drug up to week 48
|
|
Open-label Extension Period: Number of Participants With TEAEs, Serious TEAEs, Related TEAEs, Related TEAEs and TEAEs With Severity of Greater Than or Equal to 3
Lasso di tempo: Open-Label Extension Period: From Week 48 up to end of study (approximately 5 years)
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious & non-serious TEAEs. Severity of abnormalities was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE. |
Open-Label Extension Period: From Week 48 up to end of study (approximately 5 years)
|
|
Double-blind Period: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of Mitapivat
Lasso di tempo: Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 36
|
Area under the concentration-time curve from time zero to Tlast on dosing day, calculated using the linear-log trapezoidal rule. |
Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 36
|
|
Double-blind Period: Last Quantifiable Plasma Concentration (Clast) of Mitapivat
Lasso di tempo: Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 36
|
Clast is the last quantifiable concentration after a single dose or within the dosing interval (tau) for multiple doses. |
Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 36
|
Collaboratori e investigatori
Sponsor
Investigatori
- Cattedra di studio: Medical Affairs, Agios Pharmaceuticals, Inc.
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- AG348-C-018
- 2021-000212-34 (Numero EudraCT)
- 2024-512747-23-00 (Ctis)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .